Temporal associations of B and T cell immunity with robust vaccine responsiveness in a 16-week interval BNT162b2 regimen

[1]  M. Gale,et al.  Imprinted SARS-CoV-2-specific memory lymphocytes define hybrid immunity , 2022, Cell.

[2]  D. Vézina,et al.  SARS-CoV-2 Omicron Spike recognition by plasma from individuals receiving BNT162b2 mRNA vaccination with a 16-week interval between doses , 2021, bioRxiv.

[3]  P. Demers,et al.  Immunogenicity of Extended mRNA SARS-CoV-2 Vaccine Dosing Intervals. , 2021, JAMA.

[4]  M. Hernán,et al.  Comparative Effectiveness of BNT162b2 and mRNA-1273 Vaccines in U.S. Veterans , 2021, New England Journal of Medicine.

[5]  Lindsay N. Carpp,et al.  Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial , 2021, Science.

[6]  Aaron M. Rosenfeld,et al.  mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern , 2021, Science.

[7]  Rosalind J Wright,et al.  Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine , 2021, Cell.

[8]  D. Vézina,et al.  Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval between doses , 2021, Cell Host & Microbe.

[9]  O. Levtzion-korach,et al.  Safety and humoral responses to BNT162b2 mRNA vaccination of SARS-CoV-2 previously infected and naive populations , 2021, Scientific Reports.

[10]  P. Tighe,et al.  Two doses of the SARS-CoV-2 BNT162b2 vaccine enhance antibody responses to variants in individuals with prior SARS-CoV-2 infection , 2021, Science Translational Medicine.

[11]  E. Wherry,et al.  Rapid induction of antigen-specific CD4+ T cells is associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA vaccination , 2021, Immunity.

[12]  Sagar,et al.  Rapid and stable mobilization of CD8+ T cells by SARS-CoV-2 mRNA vaccine , 2021, Nature.

[13]  D. Skowronski,et al.  Single-dose mRNA vaccine effectiveness against SARS-CoV-2 in healthcare workers extending 16 weeks post-vaccination: a test-negative design from Quebec, Canada , 2021, medRxiv.

[14]  R. Bruton,et al.  Differential immunogenicity of BNT162b2 or ChAdOx1 vaccines after extended-interval homologous dual vaccination in older people , 2021, Immunity & ageing : I & A.

[15]  E. Wherry,et al.  Altered cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. , 2021, medRxiv.

[16]  Y. Saeys,et al.  Analyzing high-dimensional cytometry data using FlowSOM , 2021, Nature Protocols.

[17]  D. Vézina,et al.  A single dose of the SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and T cell responses , 2021, Cell Host & Microbe.

[18]  E. Wherry,et al.  CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer , 2021, Nature Medicine.

[19]  V. Martel-Laferrière,et al.  Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8 months post-symptom onset , 2021, Cell Reports Medicine.

[20]  K. Schnatbaum,et al.  Cross-reactive CD4+ T cells enhance SARS-CoV-2 immune responses upon infection and vaccination , 2021, Science.

[21]  L. Stamatatos,et al.  mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection , 2021, Science.

[22]  A. Fiore-Gartland,et al.  Evidence for antibody as a protective correlate for COVID-19 vaccines , 2021, Vaccine.

[23]  Jonathan C. Brown,et al.  Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine , 2021, The Lancet.

[24]  J. Salomon,et al.  Alternative Dose Allocation Strategies to Increase Benefits From Constrained COVID-19 Vaccine Supply , 2021, Annals of Internal Medicine.

[25]  A. Paltiel,et al.  Speed Versus Efficacy: Quantifying Potential Tradeoffs in COVID-19 Vaccine Deployment , 2021, Annals of Internal Medicine.

[26]  M. Fay,et al.  Standardization of ELISA protocols for serosurveys of the SARS-CoV-2 pandemic using clinical and at-home blood sampling , 2021, Nature communications.

[27]  J. Mascola,et al.  Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine , 2020, The New England journal of medicine.

[28]  P. Dormitzer,et al.  Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020, The New England journal of medicine.

[29]  D. Weissman,et al.  SARS-CoV-2 mRNA Vaccines Foster Potent Antigen-Specific Germinal Center Responses Associated with Neutralizing Antibody Generation , 2020, Immunity.

[30]  P. Dormitzer,et al.  COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses , 2020, Nature.

[31]  N. Hacohen,et al.  Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity , 2020, Science.

[32]  F. Krammer.  SARS-CoV-2 vaccines in development , 2020, Nature.

[33]  S. Nahnsen,et al.  Specific Induction of Double Negative B Cells During Protective and Pathogenic Immune Responses , 2020, bioRxiv.

[34]  B. Reinius,et al.  Natural killer cell immunotypes related to COVID-19 disease severity , 2020, Science Immunology.

[35]  L. Fugger,et al.  Recovery from COVID-19 in a B-cell-depleted multiple sclerosis patient , 2020, Multiple sclerosis.

[36]  S. Mallal,et al.  Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans , 2020, Science.

[37]  V. Martel-Laferrière,et al.  Decline of Humoral Responses against SARS-CoV-2 Spike in Convalescent Individuals , 2020, mBio.

[38]  M. Hall,et al.  Serologic cross-reactivity of SARS-CoV-2 with endemic and seasonal Betacoronaviruses , 2020, medRxiv.

[39]  Matthew S. Miller,et al.  Cross-sectional evaluation of humoral responses against SARS-CoV-2 Spike , 2020, bioRxiv.

[40]  J. Greenbaum,et al.  Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals , 2020, Cell.

[41]  D. Kaufmann,et al.  Persistent expansion and Th1-like skewing of HIV-specific circulating T follicular helper cells during antiretroviral therapy , 2020, EBioMedicine.

[42]  A. Walls,et al.  Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein , 2020, Cell.

[43]  G. Herrler,et al.  SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor , 2020, Cell.

[44]  M. Nussenzweig,et al.  Combination anti-HIV-1 antibody therapy is associated with increased virus-specific T cell immunity , 2020, Nature Medicine.

[45]  K. Black,et al.  bioRxiv: the preprint server for biology , 2019, bioRxiv.

[46]  R. Wyatt,et al.  Altered differentiation is central to HIV-specific CD4+ T cell dysfunction in progressive disease , 2019, Nature Immunology.

[47]  S. Crotty.  T Follicular Helper Cell Biology: A Decade of Discovery and Diseases. , 2019, Immunity.

[48]  Lai Guan Ng,et al.  Dimensionality reduction for visualizing single-cell data using UMAP , 2018, Nature Biotechnology.

[49]  G. Gibson,et al.  Distinct Effector B Cells Induced by Unregulated Toll‐like Receptor 7 Contribute to Pathogenic Responses in Systemic Lupus Erythematosus , 2018, Immunity.

[50]  B. Pulendran,et al.  Th1/Th17 polarization persists following whole-cell pertussis vaccination despite repeated acellular boosters , 2018, The Journal of clinical investigation.

[51]  S. Kaech,et al.  The multifaceted role of CD4+ T cells in CD8+ T cell memory , 2016, Nature Reviews Immunology.

[52]  Sean C. Bendall,et al.  Data-Driven Phenotypic Dissection of AML Reveals Progenitor-like Cells that Correlate with Prognosis , 2015, Cell.

[53]  Timothy L. Tickle,et al.  Associations between host gene expression, the mucosal microbiome, and clinical outcome in the pelvic pouch of patients with inflammatory bowel disease , 2015, Genome Biology.

[54]  W. Paul,et al.  Mechanisms Underlying Lineage Commitment and Plasticity of Helper CD4+ T Cells , 2010, Science.

[55]  C. Guillén,et al.  A novel method for isolation of human lung T cells from lung resection tissue reveals increased expression of GAPDH and CXCR6 , 2009, Journal of immunological methods.

[56]  M. Fei,et al.  IL-22 mediates mucosal host defense against Gram-negative bacterial pneumonia , 2008, Nature Medicine.

[57]  Mario Roederer,et al.  Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major , 2007, Nature Medicine.

[58]  E. Milner,et al.  A New Population of Cells Lacking Expression of CD27 Represents a Notable Component of the B Cell Memory Compartment in Systemic Lupus Erythematosus1 , 2007, The Journal of Immunology.

[59]  R. Locksley,et al.  IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge , 2007, Nature Immunology.

[60]  S. Tangye,et al.  Identification of Functional Human Splenic Memory B Cells by Expression of CD148 and CD27 , 1998, The Journal of experimental medicine.

[61]  L. Hood,et al.  Expression of IgD may use both DNA rearrangement and RNA splicing mechanisms. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[62]  A. Iwasaki,et al.  CTL mobilization to virus-infected tissue requires CD4+ T cell help , 2009, Nature.